Ovid Therapeutics (NASDAQ: OVID) insider transactions
In the twelve months to 10 November 2026, executives and directors of Ovid Therapeutics reported 2 open-market sales of 20,197 shares ($29,286) and 0 open-market purchases, by 2 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 6 July 2026 | Carter Charles Ross | Chief Financial Officer | Grant or award | +50,000 | — | 94,375 | Form 4 |
| 7 April 2026 | Papadopoulos Stelios | Director | Grant or award | +17,578 | $2.56 | 217,578 | Form 4 |
| 7 April 2026 | Friedman Bart | Director | Grant or award | +8,789 | $2.56 | 8,789 | Form 4 |
| 7 April 2026 | Fitzgerald Kevin Joseph | Director | Grant or award | +17,578 | $2.56 | 17,578 | Form 4 |
| 23 March 2026 | Levin Jeremy M | Executive Chairman | Option exercise | +47,333 | $1.40 | 3,735,048 | Form 4 |
| 26 February 2026 | Rona Jeffrey A | Cbfo | Grant or award | +68,125 | — | 156,313 | Form 4 |
| 23 February 2026 | Rona Jeffrey A | Cbfo | Open-market sale | −8,541 | $1.45 | 88,188 | Form 4 |
| 23 February 2026 | Alexander Margaret A. | President and CEO | Open-market sale | −11,656 | $1.45 | 61,750 | Form 4 |
| 15 December 2025 | Levin Jeremy M | CEO | Conversion | +71,000 | — | 3,687,715 | Form 4 |
| 8 December 2025 | Takeda Pharmaceuticals U.S.A., Inc. | — | Conversion | +1,250,000 | — | 7,000,000 | Form 4 |
| 26 February 2025 | Rona Jeffrey A | Cbfo | Open-market sale | −3,902 | $0.56 | 67,973 | Form 4 |
| 26 February 2025 | Alexander Margaret A. | President and COO | Open-market sale | −5,279 | $0.56 | 73,406 | Form 4 |
| 20 February 2025 | Alexander Margaret A. | President and COO | Grant or award | +43,750 | — | 78,685 | Form 4 |
| 20 February 2025 | Rona Jeffrey A | Cbfo | Grant or award | +43,750 | — | 71,875 | Form 4 |
| 27 January 2025 | Alexander Margaret A. | President and COO | Open-market purchase | +6,810 | $0.73 | 34,935 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Ovid Therapeutics page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.